MPM BioImpact’s uniQure QURE Stock Holding History

MPM BioImpact’s Portfolio QURE Stock Details QURE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.5M	Sell	1,225,855 -143,376	-10%	-$3.75M	3.44%	11
2026 Q1	$22.4M	Sell	1,369,231 -12,397	-0.9%	-$251K	1.73%	27
2025 Q4	$33.1M	Buy	+1,381,628	New	+$53.3M	3.78%	8
2023 Q2	–	Sell	-348,224	Closed	-$7.01M	–	37
2023 Q1	$7.01M	Sell	348,224 -591,742	-63%	-$12.4M	1.82%	16
2022 Q4	$21.3M	Buy	+939,966	New	+$20.3M	5.53%	6

Other funds holding QURE

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

MPM BioImpact's QURE Position: Q2 2026 in Review

MPM BioImpact reduced its uniQure (QURE) stake by 10% in Q2 2026, selling an estimated $3.75M and leaving 1,225,855 shares worth $56.5M. The position accounts for 3.44% of the portfolio, ranked #11.

MPM BioImpact first reported a position in QURE in Q4 2022 and has held it in 5 quarters since. 254 funds tracked by Wall St. Rank hold QURE as of Q2 2026.

MPM BioImpact held 1,225,855 shares of uniQure worth $56.5M as of Q2 2026.
MPM BioImpact sold 143,376 uniQure shares in Q2 2026, an estimated $3.75M.
uniQure made up 3.44% of MPM BioImpact's portfolio in Q2 2026, its #11 holding.
MPM BioImpact first reported a position in uniQure in Q4 2022 and has held it in 5 quarters since.
254 funds tracked by Wall St. Rank held uniQure as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.